To receive important alerts and updates from Gold Coast Primary Health Network, please submit the form below.
To receive important alerts and updates from Gold Coast Primary Health Network, please submit the form below.
The National Clinical Evidence Taskforce (NCET) has incorporated the preliminary results of the PANORAMIC trial into the body of evidence for oral antiviral molnupiravir (Lagevrio).
This large (25,783 participants) open-label randomised controlled trial was conducted in the UK, in patients who had multiple SARS-CoV-2 vaccine doses, during the Omicron wave, comparing molnupiravir to standard care.
The NECT Drug Treatments Panel, Care of Older People Panel, Expert Advisors in Aged Care, Guidelines Leadership Group and Steering Committee have considered this research and determined that there is now high certainty evidence that molnupiravir does not have an impact on the combined endpoint of hospitalisation and/or mortality in multiple-vaccinated adults with mild COVID-19 and one or more risk factors for disease progression.
The PANORAMIC trial results strengthen the NCET’s existing position that nirmaltrelvir plus ritonavir (Paxlovid) and remdesivir (Veklury) are the preferred antivirals treatments for mild COVID, and that molnupiravir is not for routine use.
As a result, the NCET has made a conditional recommendation against: Do not routinely use molnupiravir for the treatment of COVID-19.
For further details, click here.
So we can provide you with the most accurate information,
please tell us a little more about yourself
